PKP-007 Pharmacist led rapid point of care cytochrome p 2C19 genotyping for individualisation of antiplatelet therapy

BackgroundThe presence of the CYP2C19 loss of function *2 allele is associated with a decreased antiplatelet effect in clopidogrel treated patients. Since about 50% of major adverse cardiac events occur within the first 2 days post-percutaneous coronary intervention (PCI), a rapid CYP2C19*2 genotype result is important to individualise antiplatelet therapy at the start of treatment.PurposeTo apply a pharmacist led process to individualise antiplatelet therapy guided by CYP2C19*2 genotyping using the rapid point of care (POC) Spartan RX assay (Spartan Bioscience) in patients undergoing PCI.Material and methodsFollowing ethics approval and written informed consent, patients undergoing PCI with stent deployment for acute coronary syndrome or stable angina, and who were candidates for dual antiplatelet therapy, were recruited over a 3 month period by non-probability sampling. Exclusion criteria were patients 75 years old, body weight